Search Results - "Grande Pulido, E."

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes by Alfaro, C, Suarez, N, Gonzalez, A, Solano, S, Erro, L, Dubrot, J, Palazon, A, Hervas-Stubbs, S, Gurpide, A, Lopez-Picazo, J M, Grande-Pulido, E, Melero, I, Perez-Gracia, J L

“…Vascular endothelial growth factor (VEGF) inhibits differentiation and maturation of dendritic cells (DC), suggesting a potential immunosuppressive role for…”
Get full text

Cytokine and endocrine signaling in prostate cancer by Puente Vazquez, J., Grande Pulido, E., Anton Aparicio, L. M.

“…Prostate epithelial and stromal cells develop paracrine interactions, which may be responsible for the occurrence and progression of prostate pathologies…”
Get full text

Cost of metastatic colorectal cancer drugs per month of life gained in Spain by Vieitez de Prado, J., Encinas García, S., Grande Pulido, E., Sánchez Nieto, R., González Moreno, S., Garrán del Río, C., Alonso Casado, O., Ortega Pérez, G., Mombiedro Lozano, C., Grasso Cicala, S.

Get full text

Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array by Perez-Gracia, J L, Prior, C, Guillén-Grima, F, Segura, V, Gonzalez, A, Panizo, A, Melero, I, Grande-Pulido, E, Gurpide, A, Gil-Bazo, I, Calvo, A

“…Background: Several drugs are available to treat metastatic renal-cell carcinoma (MRCC), and predictive markers to identify the most adequate treatment for…”
Get full text

Interstitial pneumonitis and lung fibrosis during adjuvant treatment of melanoma with interferon alpha according to the Kirkwood schedule by Puente Vázquez, J, Moreno Antón, F, Grande Pulido, E, López Tarruella-Cobo, S, Pérez Segura, P, Díaz-Rubio, E

Get more information

Fructose transporter GLUT5 expression in clear renal cell carcinoma by Medina Villaamil, V, Aparicio Gallego, G, Valbuena Rubira, L, García Campelo, R, Valladares-Ayerbes, M, Grande Pulido, E, Victoria Bolós, M, Santamarina Caínzos, I, Antón Aparicio, L M

“…Renal cell carcinomas (RCC) can be subclassified for general purposes into clear cell, papillary cell, chromophobe cell carcinomas and oncocytomas. Other…”
Get full text

2408TiP DISCUS: A randomised phase II study of 3 vs 6 cycles of chemotherapy followed by maintenance avelumab in advanced urothelial cancer - Wearable devices and circulating biomarkers assessing quality of life and surrogate efficacy endpoints by Jackson-Spence, F., Marin, A. Pinto, Puente, J., Molina-Cerrillo, J., Hussain, S.A., Ackerman, C., Bonsu, N., Kelly, J., Loriot, Y., Powles, T.B., Pulido, E. Grande

Get full text

1209 SU14813 induces mitotic catastrophe in a wide-spectrum of tumour models independently of the expression of active receptor tyrosine kinase targets by Navarro-Palou, M, Martin, J, Ros, T, Gutierrez, A, Saus, C, Grande-Pulido, E, Alemany, R, Vogler, O, Besalduch, J, Martinez-Serra, J

Get full text

Neutropenia inducida por fármacos antineoplásicos: utilización de los factores estimulantes de colonias de granulocitos by Carrato, A., Guillén-Ponce, C., Grande-Pulido, E.

“…Los tratamientos farmacológicos del cáncer cursan con neutropenia en un elevado porcentaje de casos. La utilización de factores estimulantes de colonias de…”
Get full text

147P Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice by Molina Cerrillo, J., Ortego, I., Pinto Marin, A., Alonso Gordoa, T., Puente, J., Arranz Arija, J.A., Lopez Criado, M.P., Gonzalez Morales, A., Vidal Cassinello, N., Castellano Gauna, D.E., Sevillano Fernandez, E., Garcia Donas, J., Grande Pulido, E.

Get full text

1338P Cost-effectiveness and direct impact analysis of clinical research in the clinical approach of metastatic renal cell carcinoma and neuroendocrine tumors in a large public Spanish university hospital by García-Garro, S., Gajate Borau, P., Gómez de Salazar, E., Alonso Gordoa, T., Rodriguez Sagrado, M.Á., Molina Cerrillo, J., Manzano Espinosa, L., Bermejo Vicedo, T., Carrato Mena, A., Díez Gómez, J.J., Grande Pulido, E.

Get full text

1897P Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations by Massari, F., Pulido, E. Grande, Bamias, A., Iacovelli, R., Cerrillo, J. Molina, Procopio, G., Fiala, O., Myint, Z.W., De Giorgi, U.F.F., Buchler, T., Santini, D., Büttner, T., Roviello, G., Pichler, M., Bourlon de los Rios, M.T., Rizzo, A., Monteiro, F.S.M., Buti, S., Porta, C.G., Santoni, M.

Get full text

O-2 Overall survival and long-term safety data from the NETTER-1 trial: 177-Lu-Dotatate vs. high-dose octreotide in patients with progressive midgut NETs by Strosberg, J., Caplin, M., Kunz, P., Ruszniewski, P., Bodei, L., Hendifar, A., Mittra, E., Wolin, E., Yao, J., Pavel, M., Grande Pulido, E., Van Cutsem, E., Seregni, E., Duarte, H., Gericke, G., Bartalotta, A., Demange, A., Mutevelic, S., Krenning, E.

Get full text

1735O PD-L1 expression on immune cells by SP142 co-localises with dendritic cells and is associated with improved overall survival (OS) with atezolizumab in patients with untreated metastatic urothelial cancer (mUC) by Grande Pulido, E., Galsky, M.D., Van Elzen, R., Banchereau, R., Peterson, M., Sedano, C., Koeppen, H., Li, H., Bamias, A., Arranz Arija, J.A., Kikuchi, E., De Santis, M., Davis, I.D., Mellman, I., Oh, S., Williams, P., Bernhard, S., Lee, C.P., Kockx, M., Mariathasan, S.

Get full text

P-040Cost of metastatic colorectal cancer drugs per month of life gained in Spain by Vieitez de Prado, J, Encinas García, S, Grande Pulido, E, Sánchez Nieto, R, González Moreno, S, Garrán del Río, C, Alonso Casado, O, Ortega Pérez, G, Mombiedro Lozano, C, Grasso Cicala, S

Get full text

A phase II trial of palbociclib in metastatic grade 1/2 pancreatic neuroendocrine tumors: The PALBONET study on behalf of the Spanish Taskforce Group of Neuroendocrine Tumors (GETNE) by Grande Pulido, E., Teule, A., Alonso-Gordoa, T., Jiménez-Fonseca, P., Benavent, M., Capdevila, J., Custodio, A., Vera, R., Munarriz, J., La Casta-Muñoa, A., Garcia-Carbonero, R.

Get full text

Atezolizumab (atezo) in platinum (plat)-treated locally advanced/metastatic urothelial carcinoma (mUC): Updated OS, safety and biomarkers from the Ph II IMvigor210 study by Loriot, Y., Rosenberg, J.E., Powles, T.B., Necchi, A., Hussain, S., Morales, R., Retz, M., Niegisch, G., Duran, I., Theodore, C., Perez-Gracia, J.L., Grande Pulido, E., Thåström, A., Danner, B., Mariathasan, S., Abidoye, O., van der Heijden, M.

Get full text

28MO Predictive biomarkers of response to axitinib in patients with advanced EP-NETs enrolled in the AXINET trial (GETNE 1107): Underlying molecular mechanisms by Lens-Pardo, A., Carretero-Puche, C., Antón Pascual, B., Capdevila Castillon, J., Benavent, M., Jimenez Fonseca, P., Grande Pulido, E., Perna, C., Caminoa, A., Rubio-Cuesta, B., Sarmentero, J., Gil-Calderón, B., Soldevilla, B., Garcia-Carbonero, R.

Get full text

175P Safety and preliminary efficacy of GEN1042 (DuoBody-CD40x4-1BB) combination therapy in patients with advanced solid tumors by Melero, I., Grande Pulido, E., De Miguel Luken, M.J., Johnson, M.L., Bauman, J.R., Moreno Garcia, V., Walter, A.O., Adams, H., Türeci, Ö., Russo, G., Sahin, U., Steinberg, J., Ahmadi, T., Felip, E.

Get full text

Phase 2, open-label study of ceritinib in patients (pts) with advanced non-lung solid tumors and hematological malignancies characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK) using a flexible adaptive design: ASCEND-10 by Kiss, I., Rodón, J., Pulido, E. Grande, Rha, S.Y., Sathornsumetee, S., Hess, G., Eigendorff, E., Cesic, D., Sutradhar, S., Pramanik, B., Kim, T.M.

Get full text